Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model

Anna P. Durbin

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore

Liesbeth Van Wesenbeeck

Johnson & Johnson, Beerse, Belgium

Kristen K. Pierce

University of Vermont College of Medicine, Burlington

Guillermo Herrera-Taracena

Johnson & Johnson, Horsham, PA

Laura Ebone

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore

Annemie Buelens

Johnson & Johnson, Beerse, Belgium

Patricia Lutton

University of Vermont College of Medicine, Burlington

Beulah P. Sabundayo

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore

Veerle Van Eygen

Johnson & Johnson, Beerse, Belgium

Kim De Clerck

Johnson & Johnson, Beerse, Belgium

Isabel Fetter

University of Vermont College of Medicine, Burlington

Natalia V. Voge

Johnson & Johnson, Spring House, PA

Xi Fang

Nele Goeyvaerts

Johnson & Johnson, Beerse, Belgium

Yannick Vandendijck

Johnson & Johnson, Beerse, Belgium

Jeffrey Mayfield

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore

Oliver Lenz

Sandra De Meyer

Johnson & Johnson, Beerse, Belgium

Thomas N. Kakuda

Johnson & Johnson, San Diego, CA

Huili He

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore

Emérito Amaro-Carambot

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD

Ruxandra Draghia Akli

Marya Carmolli

University of Vermont College of Medicine, Burlington

Tine De Marez

Johnson & Johnson, Spring House, PA

Stephen S. Whitehead

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD

Marnix van Loock

Freya Rasschaert

Johnson & Johnson, Beerse, Belgium